MARKET

KARD

KARD

Kardigan, Inc.
NASDAQ
24.64
+0.19
+0.76%
After Hours: 24.64 0 0.02% 19:38 07/10 EDT
OPEN
24.40
PREV CLOSE
24.45
HIGH
24.88
LOW
22.15
VOLUME
338.75K
TURNOVER
--
52 WEEK HIGH
27.00
52 WEEK LOW
16.25
MARKET CAP
2.16B
P/E (TTM)
-39.2527
1D
5D
1M
3M
1Y
5Y
1D
Banking Heavyweights To Kick Off Earnings Next Week
Seeking Alpha · 1d ago
Catalyst Watch: Bank earnings, Netflix results, Alzheimer's conference
Seeking Alpha · 2d ago
Private Markets: Joulent’s $1.75B round leads week of private company raises
TipRanks · 3d ago
Opening Day: Bending Spoons tops pricing range in market debut
TipRanks · 6d ago
Weekly Report: what happened at KARD last week (0629-0703)?
Weekly Report · 6d ago
Opening Day: Sinda, Doncasters, DSC Holdings begin trading
TipRanks · 06/30 13:40
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 06/30 12:05
Weekly Report: what happened at KARD last week (0622-0626)?
Weekly Report · 06/29 10:37
More
About KARD
Kardigan, Inc. is a clinical-stage precision therapeutics company. It is developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Its pipeline of products includes Danicamtiv, Ataciguat and Tonlamarsen. Danicamtiv is an investigational oral cardiac atrial and ventricular myosin activator for the treatment of genetic dilated cardiomyopathy caused by pathogenic variants in myosin heavy chain 7 (MYH7) and titin, the common sarcomeric gene variants. Ataciguat is an investigational oral, once-daily soluble guanylate cyclase activator aimed at slowing the progression of calcific aortic valve stenosis in patients with moderate diseases. Tonlamarsen is an investigational liver-directed antisense oligonucleotide administered once-monthly via subcutaneous injection, targeting hepatic angiotensinogen for the management of blood pressure in acute severe hypertension post-hospitalization. Prolaio is a clinical intelligence platform.

Webull offers Kardigan, Inc. stock information, including NASDAQ: KARD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KARD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KARD stock methods without spending real money on the virtual paper trading platform.